Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

DOI Web Site Web Site 被引用文献1件 参考文献27件 オープンアクセス
  • Kurihara Momoko
    Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
  • Kabata Hiroki
    Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
  • Irie Misato
    Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
  • Fukunaga Koichi
    Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine

抄録

<p>Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, is the latest biologic for asthma. To evaluate the efficacy and mechanism of tezepelumab in asthma, the PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, and DESTINATION studies have been conducted. These results suggested that tezepelumab is a broad-target biologic, which is expected to be effective in patients with poorly controlled moderate to severe asthma regardless of the phenotype, although its efficacy in oral corticosteroids-dependent asthma, biological mechanism in non-type 2 phenotype, and long-term safety remain unknown. In this review, we summarize the results of clinical trials of tezepelumab in asthma and discuss the differences between tezepelumab and other biologics.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (27)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ